Patients Will Be Included With A Stable But Active Disease As Defined Diagnosis Of Systemic Sclerosis According To Acr Eular Classification By Eustar 2 5 Or To Patients With A Worsening Disease Despite Low Dose Steroids And At Least 2 Immunosuppressive Treatment Including Dmards Methotrexate Azathioprine Mycophenolate Mofetil And Or A Biological Dmard Rituximab Or Tocilizumab For At Least 6 Months clinical trials

Explore recruiting patients will be included with a stable but active disease as defined diagnosis of systemic sclerosis according to acr eular classification by eustar 2 5 or to patients with a worsening disease despite low dose steroids and at least 2 immunosuppressive treatment including dmards methotrexate azathioprine mycophenolate mofetil and or a biological dmard rituximab or tocilizumab for at least 6 months clinical trials.

Patients Will Be Included With A Stable But Active Disease As Defined Diagnosis Of Systemic Sclerosis According To Acr Eular Classification By Eustar 2 5 Or To Patients With A Worsening Disease Despite Low Dose Steroids And At Least 2 Immunosuppressive Treatment Including Dmards Methotrexate Azathioprine Mycophenolate Mofetil And Or A Biological Dmard Rituximab Or Tocilizumab For At Least 6 Months trials by city

Patients Will Be Included With A Stable But Active Disease As Defined Diagnosis Of Systemic Sclerosis According To Acr Eular Classification By Eustar 2 5 Or To Patients With A Worsening Disease Despite Low Dose Steroids And At Least 2 Immunosuppressive Treatment Including Dmards Methotrexate Azathioprine Mycophenolate Mofetil And Or A Biological Dmard Rituximab Or Tocilizumab For At Least 6 Months in Toronto Patients Will Be Included With A Stable But Active Disease As Defined Diagnosis Of Systemic Sclerosis According To Acr Eular Classification By Eustar 2 5 Or To Patients With A Worsening Disease Despite Low Dose Steroids And At Least 2 Immunosuppressive Treatment Including Dmards Methotrexate Azathioprine Mycophenolate Mofetil And Or A Biological Dmard Rituximab Or Tocilizumab For At Least 6 Months in Vancouver Patients Will Be Included With A Stable But Active Disease As Defined Diagnosis Of Systemic Sclerosis According To Acr Eular Classification By Eustar 2 5 Or To Patients With A Worsening Disease Despite Low Dose Steroids And At Least 2 Immunosuppressive Treatment Including Dmards Methotrexate Azathioprine Mycophenolate Mofetil And Or A Biological Dmard Rituximab Or Tocilizumab For At Least 6 Months in Montreal Patients Will Be Included With A Stable But Active Disease As Defined Diagnosis Of Systemic Sclerosis According To Acr Eular Classification By Eustar 2 5 Or To Patients With A Worsening Disease Despite Low Dose Steroids And At Least 2 Immunosuppressive Treatment Including Dmards Methotrexate Azathioprine Mycophenolate Mofetil And Or A Biological Dmard Rituximab Or Tocilizumab For At Least 6 Months in Calgary Patients Will Be Included With A Stable But Active Disease As Defined Diagnosis Of Systemic Sclerosis According To Acr Eular Classification By Eustar 2 5 Or To Patients With A Worsening Disease Despite Low Dose Steroids And At Least 2 Immunosuppressive Treatment Including Dmards Methotrexate Azathioprine Mycophenolate Mofetil And Or A Biological Dmard Rituximab Or Tocilizumab For At Least 6 Months in Edmonton Patients Will Be Included With A Stable But Active Disease As Defined Diagnosis Of Systemic Sclerosis According To Acr Eular Classification By Eustar 2 5 Or To Patients With A Worsening Disease Despite Low Dose Steroids And At Least 2 Immunosuppressive Treatment Including Dmards Methotrexate Azathioprine Mycophenolate Mofetil And Or A Biological Dmard Rituximab Or Tocilizumab For At Least 6 Months in Ottawa Patients Will Be Included With A Stable But Active Disease As Defined Diagnosis Of Systemic Sclerosis According To Acr Eular Classification By Eustar 2 5 Or To Patients With A Worsening Disease Despite Low Dose Steroids And At Least 2 Immunosuppressive Treatment Including Dmards Methotrexate Azathioprine Mycophenolate Mofetil And Or A Biological Dmard Rituximab Or Tocilizumab For At Least 6 Months in Winnipeg Patients Will Be Included With A Stable But Active Disease As Defined Diagnosis Of Systemic Sclerosis According To Acr Eular Classification By Eustar 2 5 Or To Patients With A Worsening Disease Despite Low Dose Steroids And At Least 2 Immunosuppressive Treatment Including Dmards Methotrexate Azathioprine Mycophenolate Mofetil And Or A Biological Dmard Rituximab Or Tocilizumab For At Least 6 Months in Quebec City Patients Will Be Included With A Stable But Active Disease As Defined Diagnosis Of Systemic Sclerosis According To Acr Eular Classification By Eustar 2 5 Or To Patients With A Worsening Disease Despite Low Dose Steroids And At Least 2 Immunosuppressive Treatment Including Dmards Methotrexate Azathioprine Mycophenolate Mofetil And Or A Biological Dmard Rituximab Or Tocilizumab For At Least 6 Months in Hamilton Patients Will Be Included With A Stable But Active Disease As Defined Diagnosis Of Systemic Sclerosis According To Acr Eular Classification By Eustar 2 5 Or To Patients With A Worsening Disease Despite Low Dose Steroids And At Least 2 Immunosuppressive Treatment Including Dmards Methotrexate Azathioprine Mycophenolate Mofetil And Or A Biological Dmard Rituximab Or Tocilizumab For At Least 6 Months in Kitchener Patients Will Be Included With A Stable But Active Disease As Defined Diagnosis Of Systemic Sclerosis According To Acr Eular Classification By Eustar 2 5 Or To Patients With A Worsening Disease Despite Low Dose Steroids And At Least 2 Immunosuppressive Treatment Including Dmards Methotrexate Azathioprine Mycophenolate Mofetil And Or A Biological Dmard Rituximab Or Tocilizumab For At Least 6 Months in London Patients Will Be Included With A Stable But Active Disease As Defined Diagnosis Of Systemic Sclerosis According To Acr Eular Classification By Eustar 2 5 Or To Patients With A Worsening Disease Despite Low Dose Steroids And At Least 2 Immunosuppressive Treatment Including Dmards Methotrexate Azathioprine Mycophenolate Mofetil And Or A Biological Dmard Rituximab Or Tocilizumab For At Least 6 Months in Halifax Patients Will Be Included With A Stable But Active Disease As Defined Diagnosis Of Systemic Sclerosis According To Acr Eular Classification By Eustar 2 5 Or To Patients With A Worsening Disease Despite Low Dose Steroids And At Least 2 Immunosuppressive Treatment Including Dmards Methotrexate Azathioprine Mycophenolate Mofetil And Or A Biological Dmard Rituximab Or Tocilizumab For At Least 6 Months in New York Patients Will Be Included With A Stable But Active Disease As Defined Diagnosis Of Systemic Sclerosis According To Acr Eular Classification By Eustar 2 5 Or To Patients With A Worsening Disease Despite Low Dose Steroids And At Least 2 Immunosuppressive Treatment Including Dmards Methotrexate Azathioprine Mycophenolate Mofetil And Or A Biological Dmard Rituximab Or Tocilizumab For At Least 6 Months in Los Angeles Patients Will Be Included With A Stable But Active Disease As Defined Diagnosis Of Systemic Sclerosis According To Acr Eular Classification By Eustar 2 5 Or To Patients With A Worsening Disease Despite Low Dose Steroids And At Least 2 Immunosuppressive Treatment Including Dmards Methotrexate Azathioprine Mycophenolate Mofetil And Or A Biological Dmard Rituximab Or Tocilizumab For At Least 6 Months in Chicago Patients Will Be Included With A Stable But Active Disease As Defined Diagnosis Of Systemic Sclerosis According To Acr Eular Classification By Eustar 2 5 Or To Patients With A Worsening Disease Despite Low Dose Steroids And At Least 2 Immunosuppressive Treatment Including Dmards Methotrexate Azathioprine Mycophenolate Mofetil And Or A Biological Dmard Rituximab Or Tocilizumab For At Least 6 Months in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease